| Primary |
| Prostate Cancer |
74.3% |
| Hypertension |
7.3% |
| Prostate Cancer Metastatic |
3.3% |
| Diabetes Mellitus |
1.9% |
| Insomnia |
1.6% |
| Gastritis |
1.5% |
| Benign Prostatic Hyperplasia |
1.4% |
| Gastric Ulcer |
1.1% |
| Atrial Fibrillation |
1.0% |
| Glaucoma |
0.9% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Pain |
0.8% |
| Angina Pectoris |
0.7% |
| Constipation |
0.6% |
| Metastases To Bone |
0.6% |
| Cancer Pain |
0.5% |
| Depression |
0.5% |
| Asthma |
0.4% |
| Blood Cholesterol Increased |
0.4% |
| Diabetes Mellitus Non-insulin-dependent |
0.4% |
|
| Death |
12.3% |
| Interstitial Lung Disease |
8.7% |
| Cardiac Failure |
8.4% |
| Hepatic Function Abnormal |
8.4% |
| Prostatic Specific Antigen Increased |
6.6% |
| Platelet Count Decreased |
6.0% |
| Cerebral Infarction |
5.5% |
| Renal Impairment |
5.0% |
| Renal Failure |
3.9% |
| Myocardial Infarction |
3.7% |
| Thrombocytopenia |
3.7% |
| Weight Decreased |
3.7% |
| Weight Increased |
3.7% |
| Liver Disorder |
3.4% |
| Malaise |
3.4% |
| White Blood Cell Count Decreased |
3.1% |
| Prostate Cancer |
2.9% |
| Diabetes Mellitus |
2.6% |
| Disease Progression |
2.6% |
| Malignant Neoplasm Progression |
2.4% |
|
| Secondary |
| Prostate Cancer |
56.0% |
| Product Used For Unknown Indication |
7.7% |
| Drug Use For Unknown Indication |
6.6% |
| Hypertension |
6.4% |
| Insomnia |
3.3% |
| Pain |
1.9% |
| Respiratory Tract Infection |
1.7% |
| Gastritis |
1.6% |
| Diabetes Mellitus |
1.5% |
| Metastases To Bone |
1.5% |
| Constipation |
1.5% |
| Prostate Cancer Metastatic |
1.5% |
| Benign Prostatic Hyperplasia |
1.4% |
| Glaucoma |
1.3% |
| Prostate Cancer Stage Iv |
1.2% |
| Back Pain |
1.2% |
| Prophylaxis |
1.0% |
| Bone Disorder |
0.9% |
| Cancer Pain |
0.9% |
| Blood Pressure Increased |
0.7% |
|
| Interstitial Lung Disease |
36.3% |
| Hepatic Function Abnormal |
7.7% |
| White Blood Cell Disorder |
5.1% |
| Weight Increased |
4.8% |
| Pulmonary Embolism |
4.5% |
| Prostate Cancer |
4.2% |
| Platelet Count Decreased |
3.2% |
| Prostatic Specific Antigen Increased |
3.2% |
| Renal Impairment |
3.2% |
| Loss Of Consciousness |
2.9% |
| Pleural Effusion |
2.9% |
| Pneumonia |
2.9% |
| Cerebrovascular Accident |
2.6% |
| Dyspnoea |
2.6% |
| Febrile Neutropenia |
2.6% |
| Psychotic Disorder |
2.6% |
| Neutropenia |
2.3% |
| Pyrexia |
2.3% |
| Tinnitus |
2.3% |
| Medication Error |
1.9% |
|
| Concomitant |
| Prostate Cancer |
23.9% |
| Product Used For Unknown Indication |
11.3% |
| Drug Use For Unknown Indication |
10.9% |
| Prostate Cancer Stage Iv |
9.3% |
| Hypertension |
7.1% |
| Metastases To Bone |
6.9% |
| Prostate Cancer Metastatic |
5.2% |
| Prostate Cancer Stage Ii |
4.1% |
| Pain |
3.5% |
| Prostate Cancer Stage Iii |
3.1% |
| Benign Prostatic Hyperplasia |
2.7% |
| Prophylaxis |
2.1% |
| Diabetes Mellitus |
1.8% |
| Constipation |
1.6% |
| Back Pain |
1.4% |
| Gastritis |
1.3% |
| Osteoporosis |
1.0% |
| Depression |
1.0% |
| Insomnia |
1.0% |
| Atrial Fibrillation |
0.9% |
|
| Weight Decreased |
15.5% |
| Prostate Cancer |
11.3% |
| Tooth Extraction |
8.9% |
| Prostatic Specific Antigen Increased |
8.8% |
| Vomiting |
6.5% |
| White Blood Cell Count Decreased |
5.6% |
| Interstitial Lung Disease |
4.0% |
| Osteonecrosis |
4.0% |
| Pneumonia |
3.5% |
| Death |
3.2% |
| Lung Neoplasm Malignant |
3.1% |
| Tooth Fracture |
3.1% |
| Toothache |
3.1% |
| Prostate Cancer Metastatic |
3.0% |
| Urinary Retention |
3.0% |
| Urinary Tract Infection |
2.8% |
| Wheezing |
2.8% |
| Prostate Cancer Stage Iv |
2.7% |
| Pyrexia |
2.7% |
| Pain |
2.4% |
|
| Interacting |
| Hormone Therapy |
25.6% |
| Hypertension |
20.9% |
| Gastritis |
9.3% |
| Prostate Cancer |
7.0% |
| Seasonal Allergy |
7.0% |
| Antiandrogen Therapy |
4.7% |
| Cardiac Disorder |
4.7% |
| Dry Skin |
4.7% |
| Mucosal Inflammation |
4.7% |
| Prostatic Specific Antigen Increased |
4.7% |
| Blood Cholesterol |
2.3% |
| Hyperlipidaemia |
2.3% |
| Renal Cancer Metastatic |
2.3% |
|
| Hypothyroidism |
15.4% |
| Prostatic Specific Antigen Increased |
15.4% |
| Swelling |
15.4% |
| Syncope |
15.4% |
| Drug Interaction |
7.7% |
| Joint Injury |
7.7% |
| Neoplasm Progression |
7.7% |
| Rectal Haemorrhage |
7.7% |
| Urinary Retention |
7.7% |
|
